October 7, 2015

Heat Biologics to Participate in the Annual Prostate Cancer Foundation Scientific Retreat

DURHAM, N.C., Oct. 7, 2015 (GLOBE NEWSWIRE) --**Heat Biologics, Inc.** ("Heat"), (Nasdaq:HTBX), a clinical-stage cancer immunotherapy company, announced that Taylor Schreiber, M.D., Ph.D., Chief Scientific Officer, will serve on a panel at the 22nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat in Washington, D.C. on October 7-10, 2015. In addition, Dr. Schreiber will present an overview on *ComPACT*, the company's next-generation combination immunotherapy platform.

ComPACT combines a pan-antigen T cell priming vaccine and T cell co-stimulator in a single product, offering the potential benefits of combination immunotherapy in a single drug without the need for multiple independent biologic products. Heat expects to announce its selection of the first product candidate based on the *ComPACT* platform in the first quarter of 2016.

For the past twenty-one years, the PCF has been hosting an annual scientific retreat that brings together diverse researchers in a collaborative forum to present and discuss new and largely unpublished findings for prostate cancer diagnosis, prognosis, and treatment and defines the challenges that impede progress toward better treatments and cures. For more information please visit PCF's website at www.pcf.org.

About Heat Biologics, Inc.

Heat Biologics is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" *ImPACT*™ and *ComPACT* therapeutic vaccines to combat a wide range of cancers.[i] Our therapies are designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens, together with a potent immune adjuvant called "gp96," to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer, as well as a Phase 1b trial of HS-110 (viagenpumatucel-L) in combination with a PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer. For more information please visit the company's website at www.heatbio.com.

Forward Looking Statements

This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are

based upon current beliefs, expectations and assumptions and include statements regarding the timing of the announcement of the selection of the first product candidate based on the *ComPACT* platform and the potential benefits that may be derived from*ComPACT*. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's *ImPACT* and *ComPACT* Therapy to perform as designed, the ability to timely enroll patients and complete the clinical trial on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2014 and Heat's other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

[i] *ImPACT* is a registered trademark of Heat Biologics, Inc.

CONTACT: Heat Biologics, Inc.
Jennifer Almond
Investor and Media Relations
919-240-7133
investorrelations@heatbio.com

Source: Heat Biologics